Current pharmacological treatments of osteoporosis primarily aim either to reduce excessive osteoclastic bone resorption (e.g., estrogen and bisphosphonates) or to promote osteoblastic bone formation (e.g., parathyroid hormone), and to a lesser degree, to achieve both (e.g., anti‐sclerostin [SOST] antibody). Here, SOST is linked to osteoporosis.